-Advertisement-

Tarsus CEO Bobby Azamian: Clearing Crusty Eyelids with Xdemvy

A week before Tarsus Pharmaceuticals received federal approval for its groundbreaking treatment of an eyelid inflammation that impacts 25 million Americans, CEO Bobak โ€œBobbyโ€ Azamian welcomed his first child into the world.

โ€œIt was the most exciting week of my life in two different ways,โ€ Azamian told the Business Journal.

Itโ€™s since been a whirlwind year and a half since for the father and chief executive.

Under the leadership of Azamian, Tarsus has emerged as a leading biotech innovator in Orange County. He has spearheaded the development and commercialization of Xdemvy, the first Food and Drug Administration-approved treatment for Demodex blepharitis, an inflammation of the eyelids caused by mites.

Since receiving FDA approval in mid-2023, shares of the Irvine
biopharmaceutical company have nearly tripled to $55.74 apiece with a market cap of $2.1 billion โ€“ up from $531 million in fall 2023.

โ€œWeโ€™ve been successful because weโ€™ve been able to find the โ€˜white spaceโ€™ in healthcare โ€“ we identified an area of significant unmet need and worked across channels to prepare and educate the market, understand the patient experience and demonstrate value, and drive awareness and interest in our company and brand,โ€ Azamian told the Business Journal.
Since its launch, Xdemvy has exceeded company expectations, with robust quarter-over-quarter sales growth and increased reach among eye care providers.

Sales are expected to soar 80% to $315 million this year, according to the average estimate of seven analysts.

Looking to be a leading player in the OC healthcare space, Tarsus recently disclosed plans to double its office space in Irvine by relocating to a new 60,000-square-foot corporate headquarters at Spectrum Terrace.

โ€œWeโ€™ve just found this an incredible place to build a leading eye care pharmaceutical company, and weโ€™re committed to that for the long run here in Orange County,โ€ Azamian said.

For all these reasons, the Business Journal has named Azamian as Businessperson of the Year in Orange Countyโ€™s healthcare industry. He joins two others who are playing a pivotal role in the ophthalmology industry: Thomas Burns at Glaukos Corp. and Ron Kurtz at RxSight Inc. Additionally, Gavin Herbert, the founder of Allergan, is receiving the Business Journalโ€™s first ever Lifetime Business Achievement Award (see page 1 and elsewhere).

Inspired by Animals

Azamian calls Xdemvyโ€™s journey serendipitous as the companyโ€™s research started by first looking at veterinary care.

When he and his co-founder Michael Ackermann began looking for the very best drug to treat the crusty eyelids caused by Demodex mites, they found that the โ€œbest chemistryโ€ came from animal health.

It turns out Ackermannโ€™s sister is a veterinary dermatologist. She told them that she didnโ€™t see mange in dogs and cats anymore because they were being successfully treated by a new class of chemistry known as lotilaner, a pet-friendly antiparasitic molecule used to treat conditions like mange and ticks.

โ€œAnd thatโ€™s when our ears perked up,โ€ Azamian said. “It was truly unexpected that in trying to find a great drug to treat mites, we would find it from an animal health company.โ€

Tarsus knew it could leverage lotilaner for human use, so it moved quickly to license it from Swiss-based Elanco Tiergesundheit AG.

Tarsus eventually reformulated lotilaner for human use as a topical eye drop, known as TP-03, demonstrating efficacy in pivotal trials involving over 800 patients who saw significant improvements โ€“ with some patients seeing results as early as two weeks.

โ€œItโ€™s been an incredible story where we start with the biology, we start with the target and the disease, and then we find the best chemistry out there to treat the disease,โ€ Azamian said.

Year-to-date, as of the third quarter, the company has delivered 104,400 bottles of Xdemvy to patients compared to 1,700 bottles delivered in the prior year period.

Azamian is proud that Tarsus has been able to negotiate a price point with payers such as Medicare that is affordable for patients.ย Most patients pay $50 or less for Xdemvy.

โ€œItโ€™s been a priority for me, for our entire commercial and executive team, to have a drug thatโ€™s accessible to all the patients that need it,โ€ he said.

Expanding Beyond Eye Treatments

As the company grows, Azamian said Tarsus is committed to seeking opportunities โ€œwhere we can make the greatest impact in the healthcare industry and most importantly, to patients.โ€

Tarsus, for example, is leveraging lotilaner as a โ€œpipeline in a productโ€ to address other conditions, including meibomian gland disease (MGD), rosacea and Lyme disease.

Azamian said Tarsus is โ€œjust scratching the surface of what we can ultimately doโ€ with lotilaner. Recent data presented by Tarsus showed its potential to improve symptoms of MGD in patients with Demodex blepharitis and MGD, such as fluctuating vision and redness, marking another significant milestone.

The company is also advancing Phase 2 studies for a topical rosacea treatment and an oral tablet developed for preventing Lyme disease, with promising updates anticipated this year. โ€œWe expect to announce some progress with the FDA in the early part of 2025,โ€ he said.

Tarsus Relocating to New HQ in 2026

Tarsus Pharmaceuticals, which has more than 100 of its 331 employees in Orange County, has plans to double its office space in Irvine by relocating to a new 60,000-square-foot corporate headquarters at Spectrum Terrace.

Last month, the company entered an agreement with property owner Irvine Company to lease about 59,626 square feet of office space at 17700 Laguna Canyon Road in Irvine. Monthly rent starts at $211,672.30 during the first year, or $3.55 PSF, according to a regulatory filing.

Moving its headquarters to a larger space underscores the companyโ€™s goals to expand its talent pool and become one of the leaders in eye care.

โ€œWith Xdemvy launch, we are considered a leading eye care company, and we want to build a lasting company in Orange County,โ€ CEO and Chairman Bobak โ€œBobbyโ€ Azamian told the Business Journal in a Jan. 6 interview. โ€œSo thatโ€™s why we signed that lease on a space that will allow us to expand, that will allow us to collaborate in even better ways, and really sets us up for long term success in Orange County.โ€

Azamian called the Spectrum Terrace location a โ€œstate of the artโ€ space.

โ€œThereโ€™s incredible team and collaborative facilities on site,โ€ he said. โ€œIt also has a great footprint for collaboration within the space. So, weโ€™ve got two floors, 30,000 square feet each, that will really allow us to work as a team in ways we havenโ€™t been able to even in our current great space.โ€

Azamian is targeting early 2026 for relocating the Tarsus HQ from its current space at 15440 Laguna Canyon Road.

Creating a โ€˜Miteyโ€™ Culture

While Tarsusโ€™ work is serious, the companyโ€™s first direct-to-consumer ad campaign for Xdemvy clearly demonstrates that company officials are having a bit of fun along the way.
In October, Tarsus Pharmaceuticals launched a TV commercial to promote Xdemvy.

The humorous โ€œYour Mitey Problemโ€ ad, which recently aired during this monthโ€™s Golden Globes show, features humans dressed as Demodex mites. The uninvited eyelid squatters are shown dancing on a womanโ€™s eyelid, causing redness and inflammation.

The narrator says, โ€œGot eyelid itching, crusties and swelling that wonโ€™t go away? It could be โ€ฆโ€
Then, a โ€œDemodex miteโ€ jumps on screen to declare that he is the culprit.

โ€œWeโ€™re very common and super irritating to your eyelids. But we love making ourselves comfortable here,โ€ the mite says.

The commercial goes on to say that Xdemvy, with one drop in each eye twice a day, can kill the mites in just six weeks.

โ€œWe like to do things differently at Tarsus, just because we like that,โ€ CEO Bobak โ€œBobbyโ€ Azamian said.

While itโ€™s still early days, the ad has resonated with consumers.

โ€œWeโ€™re really encouraged by what weโ€™re hearing, what weโ€™re seeing in our metrics, and we expect that [ad] to really reach millions of patients this year โ€“ and thatโ€™s our mission: to serve millions of patients.โ€

Want more from the best local business newspaper in the country?

Sign-up for our FREE Daily eNews update to get the latest Orange County news delivered right to your inbox!

Sonia Chung
Sonia Chung
Sonia Chung joined the Orange County Business Journal in 2021 as their Marketing Creative Director. In her role she creates all visual content as it relates to the marketing needs for the sales and events teams. Her responsibilities include the creation of marketing materials for six annual corporate events, weekly print advertisements, sales flyers in correspondence to the editorial calendar, social media graphics, PowerPoint presentation decks, e-blasts, and maintains the online presence for Orange County Business Journalโ€™s corporate events.
-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-